Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jubilant PharmovaBOM:530019 +0.21%71 Interest Coverage is 3.94 as of Mar. 2026, which is 2% below its 10-year median of 4.03. GuruFocus rates BOM:530019 with a GF Score™ of 71/100 and a GF Value™ of ₹1,059.60 (Fairly Valued). The stock has 5 warning signs investors should review. Among 687 Drug Manufacturers companies, Jubilant Pharmova ranks worse than 75.55% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Jubilant Pharmova's
Operating Income
for the
three
months ended in Mar. 2026 was ₹2,225 Mil. Jubilant Pharmova's Interest Expense for the
three
months ended in Mar. 2026 was ₹-565 Mil.
Jubilant Pharmova's interest coverage for the quarter that ended in Mar. 2026 was 3.94.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Jubilant Pharmova's Interest Coverage or its related term are showing as below:
BOM:530019'
s Interest Coverage Range Over the Past 10 Years
Min: 1.36 Med: 4.03 Max: 6.71
Current: 3.87
BOM:530019's Interest Coverage is ranked worse than 75.55% of 687
companies
in the Drug Manufacturers industry
Industry Median: 12.75
vs BOM:530019: 3.87
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Jubilant Pharmova Interest Coverage Related Terms
Jubilant Pharmova Interest Coverage Historical Data
* Premium members only.
The historical data trend for Jubilant Pharmova's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BOM:530019 vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jubilant Pharmova's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Pharmova Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jubilant Pharmova's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Jubilant Pharmova's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Pharmova (BOM:530019) has a Interest Coverage of 3.94 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jubilant Pharmova and its competitors. This is near median its historical median of 4.03. Over the past decade, Jubilant Pharmova's Interest Coverage has ranged from 1.36 to 6.71. According to the industry distribution chart, Jubilant Pharmova ranks #519 out of 687 companies in the Drug Manufacturers industry, placing it in the top 75.5%.
Is Jubilant Pharmova's Interest Coverage too high?
Jubilant Pharmova's current Interest Coverage of 3.94 is near median its 10-year median of 4.03. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 6.71. The Drug Manufacturers industry median Interest Coverage is 12.75. Jubilant Pharmova's value of 3.94 is 69.1% below this industry median. Based on the distribution chart, Jubilant Pharmova ranks #519 out of 687 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jubilant Pharmova has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Pharmova's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jubilant Pharmova ranks #519 out of 687 companies for Interest Coverage. This places Jubilant Pharmova in the lower half of its industry. The industry median Interest Coverage is 12.75. Jubilant Pharmova's value of 3.94 is 69.1% below this benchmark. Historically, Jubilant Pharmova's own Interest Coverage has ranged from 1.36 to 6.71 over the past decade. While the company's 10-year median is 4.03 vs. the industry median of 12.75, Jubilant Pharmova has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.75, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Pharmova's current Interest Coverage of 3.94 is 69.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Jubilant Pharmova and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Pharmova's current Interest Coverage is 3.94, which is near median its own 10-year median of 4.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Pharmova stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Pharmova (BOM:530019) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,059.60, compared to a current price of ₹1,022.25 — trading 3.5% below its estimated fair value. The current Interest Coverage is 3.94, which is near median its 10-year median of 4.03 and 69.1% below the Drug Manufacturers industry median of 12.75. Jubilant Pharmova's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Jubilant Pharmova (BOM:530019), the current Interest Coverage is 3.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Pharmova (BOM:530019) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Pharmova stock appears to be undervalued.
The current stock price of ₹1,022.25 is trading 3.5% below its estimated GF Value™ of ₹1,059.60.
GuruFocus considers Jubilant Pharmova to be Fairly Valued.
Key valuation signals for BOM:530019:
Interest Coverage: 3.94 (near median its 10-year median of 4.03)
GF Value™: ₹1,059.60 vs. price of ₹1,022.25 (3.5% below fair value)
Industry Position: 69.1% below the Drug Manufacturers median (#519 of 687)
No single metric tells the full story. See the BOM:530019 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Pharmova Ltd is an integrated pharmaceutical company. The company operates in the following segments; Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research, Development and Manufacturing Organisation; and Proprietary Novel Drugs. It generates maximum revenue from the Radiopharma segment which specializes in developing, manufacturing, commercializing, and distributing therapeutic agents in the nuclear medicine domain. Geographically, it derives a majority of its revenue from the Americas and Europe and the rest from India and the Rest of the world.
71GF Score
Get the complete analysis for BOM:530019
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530019 has been successfully added to your 
